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ABSTRACT: The aryloxy triester phosphoramidate prodrug approach has been used with
success in drug discovery. Herein, we describe the ﬁrst application of this prodrug technology
to the monophosphate derivative of the phosphoantigen HMBPP and one of its analogues.
Some of these prodrugs exhibited speciﬁc and potent activation of Vγ9/Vδ2 T-cells, which
were then able to lyse bladder cancer cells in vitro. This work highlights the promise of this
prodrug technology in the discovery of novel immunotherapeutics.
■ INTRODUCTION
Present since birth,1 Vγ9/Vδ2 T-cells represent the dominant
subtype of human γδ T-cells in adult peripheral blood.2 They
expand in response to various infections, including tuberculosis,
leprosy, typhoid, malaria, and toxoplasmosis, and studies in
primate models have suggested a role in immunity to
Mycobacterium tuberculosis.3 Interestingly, they also exhibited
an ability to target and lyse a diverse range of cancer cells in
vitro.2 Such properties have made the Vγ9/Vδ2 subset a major
focus in the therapeutic exploitation of γδ T-cells.4
Interestingly, Vγ9/Vδ2 T-cells have been shown to be
activated by small molecule phosphoantigens (PAg) such as
(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP)
and isopentenyl pyrophosphate (IPP) (Figure 1).5,6 Beyond
these natural ligands, two synthetic molecules, risedronate and
zoledronate, activate Vγ9/Vδ2 T-cells through accumulation of
IPP and are currently used in the clinic to treat osteoporosis
and some types of cancer (Figure 1).7−9
The mechanism by which these small molecule phosphoan-
tigens activate Vγ9/Vδ2 T-cells is understood to be mediated
by the type-1 transmembrane protein butyrophilin 3A1.10,11
Although conﬂicting reports exist as to whether PAgs bind to
the extracellular or intracellular domains of this transmembrane
protein, there is an increasing body of evidence that supports
the notion that these PAgs bind the intracellular B30.2 domain
of butyrophilin 3A1.10,12−15
Encouraged by Vγ9/Vδ2 T-cells’ ability to mount immune
responses toward pathogens, lyse tumor cells, as well as their
amenability to be targeted and modulated by small molecules
(PAgs and their synthetic mimics), we embarked on the
discovery of small molecules that have the potential to activate
Vγ9/Vδ2 T-cells. Given our interest in the discovery and
development of phosphorylated molecules and their prodrugs
as therapeutics,16−18 we focused our eﬀorts on the natural
phosphoantigen HMBPP as it is the most potent activator of
Vγ9/Vδ2 T-cells reported to date (Figure 1).19 HMBPP has a
pyrophosphate group, which accounts for poor drug-like
properties, namely, poor cell membrane permeability, due its
charged nature under physiological conditions (pH ≤ 7.4) and
limited in vivo stability. These properties have hindered the
development of many drugs with unmasked phosphate or
pyrophosphate groups. To overcome these drawbacks,
numerous phosphate prodrug strategies have been developed
and used with success in the discovery of mostly nucleotide
monophosphates and monophosphonates.20−22
There have been reports in the literature of the application of
the bis-pivaloyloxymethyl (bisPOM) phosphate prodrug
technology and its derivatives to HMBP and its diphospho-
nates, which resulted in potent phosphoantigens though these
were less potent than the parent phosphoantigen
HMBPP.19,23−25 Aiming to discover phosphoantigen prodrugs
that are as potent as HMBPP, we focused our work on the
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Figure 1. Chemical structures of natural phosphoantigens HMBPP
and IPP as well as synthetic molecules risedronate and zoledronate,
which activate Vγ9/Vδ2 T-cells.
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aryloxy triester phosphoramidate26 prodrug approach, in which
the monophosphate or monophosphonate groups are masked
by an aryl motif and an amino acid ester moiety. This prodrug
technology is known to be more eﬃcient in delivering
monophosphorylated molecules than the bisPOM approach.27
Over the past decade or so, it has led to at least 10 clinical
candidates with two being eventually approved for clinical
use.28 Notably, this prodrug approach has mostly been used on
nucleotide monophosphates and monophosphonates. In this
work, we applied this powerful phosphate prodrug technology
to the monophosphate derivative of the phosphoantigen
HMBPP, (E)-4-hydroxy-3-methylbut-2-enyl phosphate
(HMBP). The aryloxy triester phosphoramidate prodrugs of
the phosphoantigen HMBP will be referred to as HMBP
ProPAgens in this work.
■ RESULTS AND DISCUSSION
The synthesis of HMBP ProPAgens was similar to that
reported by Reichenberg et al.29 Brieﬂy, the hydroxyl group of
1-hydroxypropan-2-one (1) was protected with TBS in the
presence of imidazole (Scheme 1a). The ether product 2 was
then treated with a Horner−Wadsworth−Emmons reagent,
speciﬁcally triethyl phosphonoacetate, to create the double
bond with E selectivity and yield the ester product 3. This
compound, 3, was produced in a mixture of E/Z isomers with a
5:1 ratio similar to what is reported in the literature.5 The E/Z
isomers were separated by column chromatography using
solvent mixture of 5−7% diethyl ether in hexane. The two
products were then evaluated with 1H and 13C NMR utilizing
previous work by Hintz et al.5 who performed NOESY
experiments to determine the identity of each isomer. The
desired E-isomer, 3, was subsequently reduced using lithium
aluminum hydride in THF to aﬀord the key intermediate 4.
The coupling of compound 4 to phosphorochloridates to aﬀord
the desired prodrugs was achieved using standard proce-
dures.17,18 Phosphorochloridates, 9a−d, bearing methyl,
isopropyl, tert-butyl, or benzyl esters, were synthesized
following the procedure reported by Mehellou et al.17 and as
shown in Scheme 1b. These were coupled to 4 in the presence
of triethylamine or N-methylimidazole (NMI) to aﬀord the
desired HMBP ProPAgens, 5a−d, in modest yields. Notably,
NMI was only used in cases when TEA gave very low yields.
The removal of the TBS protecting group was initially pursued
using TBAF in THF.30 However, this strategy did not work in
our hands as the reaction yielded so many products and no
traces of the desired HMBP ProPAgens were detected by mass
spectroscopy. As an alternative, we used mild acidic conditions,
0.1 equiv of 1.25 M HCl in methanol, and this achieved the
TBS deprotection without degrading the phosphate masking
moieties to aﬀord the desired HMBP ProPAgens 6a−d in good
yields.
The unprotected HMBP ProPAgens 6a−d, however,
exhibited low stability and underwent rapid degradation,
which prevented their biological testing (purity <95%). In
order to get an insight into the metabolism of ProPAgens 6a−
d, compound 6d was incubated with the carboxypeptidase
cathepsin A in vitro and the reaction was monitored with 31P
NMR. The data show that after 72 h, the major metabolite had
a phosphorus peak at ∼1.95 ppm (Supporting Information
Figure S1). Mass spectroscopy analysis of these samples
showed that the degradation product, which had a 31P NMR
peak of ∼1.95 ppm, was the phosphate group masked with the
aryl motif and the amino acid ester moiety (Supporting
Information Figure S2). This indicated that the P−O bond in
HMBP ProPAgens 6a−d was labile and was cleaved oﬀ to
release the unphopshorylated PAg backbone rather than
HMBP. This may explain literature reports pursuing the
phosphonates of HMBP where the −O-P- bond was replaced
by a −CH2-P- one and lack of reports on the native HMBP
phosphate prodrugs.19
Interestingly, HMBP ProPAgens 5a−d, which had the side
chain hydroxyl group protected with a TBS moiety, exhibited
better stability than 6a−d, and hence we were able to
characterize them fully and obtain a measure of their purity
(see Supporting Information). Prodrugs 5a−d were then
investigated for their ability to activate Vγ9/Vδ2 T-cells. For
this, peripheral blood mononuclear cells (PBMCs) containing
Vγ9/Vδ2 T-cells derived from healthy donors were incubated
with increasing concentrations of HMBPP, zoledronate, or
HMBP ProPAgens 5a−d (up to 100 μM) (Figure 2a and
Figure 2b). Peripheral blood γδ T-cells lack appreciable levels
of surface CD69 or CD25 under steady state conditions, but T-
cell receptor (TCR) stimulation upregulates both T-cell
activation markers.31 PAg responsive Vγ9/Vδ2 T-cells were
then distinguished by TCR Vγ9 and Vδ2 expression and
assessed for the upregulation of CD69 and CD25.
As shown in Figure 2c and Figure 2d, the natural
phosphoantigen HMBPP showed signiﬁcant activation of
Vγ9/Vδ2 T-cells, EC50 = 0.06 nM, comparable to its reported
potency.19 Additionally, zoledronate showed a moderate
activation, EC50 ≈ 500 nM as expected (Figure 2c and Figure
Scheme 1. (a) Synthesis of HMBP ProPAgens and (b)
Synthesis of Aryl Phosphorochloridatesa
aPart a, reagents and conditions: (a) TBSCl, imidazole, DCM, rt, yield
95%; (b) triethyl phosphonoacetate, NaH, THF, 0 °C, yield 50%; (c)
LiAlH4, THF, 0 °C, yield 40%; (d) 9a−d, TEA or NMI, DCM, yields
36−56%; (e) TBAF, THF; (f) HCl, MeOH, yields 20−74%. Part b,
reagents and conditions: (g) Et2O, TEA, −78 °C, yields 54−95%. Me,
methyl; iPr, isopropyl; tBu, tert-butyl; Bn, benzyl.
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2d). The four HMBP ProPAgens 5a−d exhibited potent Vγ9/
Vδ2 T-cell activation with 5b being the most potent, EC50 =
0.45 nM, followed by 5a, EC50 = 1.38 nM. Such potency makes
HMBP ProPAgen 5b 1081 times more active than the clinically
used agent zoledronate. The other two HMBP ProPAgens also
exhibited low nanomolar activation of Vγ9/Vδ2 T-cells, 10.62
nM for 5c and 8.92 nM for 5d (Figure 2c and Figure 2d).
Impressively, CD8+ αβ T-cells, which are activated by peptides,
showed no reactivity toward HMBP ProPAgens, exemplifying
their speciﬁcity toward Vγ9/Vδ2 T-cells (Figure 2e). Notably,
the unphopshorylated backbone compound 4 did now show
any activation of Vγ9/Vδ2 T-cells (data not shown).
Next, we tested the potential for ProPAgens to sensitize the
urinary bladder carcinoma cell line T24 for targeted killing by
in vitro expanded Vγ9/Vδ2 T cells. Without sensitization,
medium pulsed T24 cells were poorly targeted by increasing
ratios of Vγ9/Vδ2 T cells, but upon pulsing for 4 h with
zoledronate or ProPAgens 5a−d, T24 cells were speciﬁcally
lysed (Figure 3a). The short pulsing period, poor lipophilicity,
and requirement to target a metabolic enzyme resulted in only
a marginal increase in speciﬁc T24 cell killing by zoledronate
(Figure 3b). In contrast, a 1000-fold lower concentration of
each ProPAgen mediated a 2- to 4-fold increase in speciﬁc lysis
of T24 over the same period (Figure 3b).
The activity across the diﬀerent HMBP ProPAgens in both
biological assays was in agreement with what is typically
observed with aryloxy triester phosphoramidate (ProTide)
prodrugs of nucleoside analogues as it correlated with the
lipophilicity and rate of degradation. The HMBP ProPAgen
with benzyl esters, e.g., 5b, has higher lipophilicity and thus
better (passive) cellular uptake. Also, the benzyl group is a
better leaving group than the other aliphatic esters, and thus the
metabolism of the benzyl ester of 5b proceeds faster than the
other ProPAgens, 5a, 5c, and 5d. Together, these explain the
superior activity of ProPAgen 5b. HMBP ProPAgen 5a also
exhibited relatively potent activation of Vγ9/Vδ2 T-cells with
EC50 = 1.38 nM. The fact that ProPAgen 5c, which has an
isopropyl ester, exhibited lower potency in activating Vγ9/Vδ2
Figure 2. Activation of human Vγ9/Vδ2+ T cells by HMBP ProPAgens. (a) Human peripheral blood mononuclear cells (PBMC) were incubated
with media or indicated concentrations of HMB-PP or zoledronate for 18 h. TCR Vγ9/Vδ2+ T cells were then assessed for the upregulation of cell
surface markers, CD69 and CD25. Data representative of n = 5. (b) As in (a), with PBMC incubated with indicated concentrations of HMBP
ProPAgens. Data representative of n = 4. (c) As in (a) and (b), with data showing titrations of each of HMB-PP, zoledronate, and HMBP
ProPAgens, alongside a medium control (M). Data from n = 4−5 donors. (d) EC50, ED50, and selectivity index (SI) values for each HMBP
ProPAgens. Speciﬁc cell death, for ED50 values, was calculated after adjusting for nonspeciﬁc cell death in medium controls. (e) CD69 and CD25
activation in CD3+ CD8+ αβ T-cells for each compound.
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T-cells as compared to 5a and 5d was surprising as often
phosphoramidate prodrugs with this ester exhibit similar
activity to those with a methyl ester. However, the less potent
activity observed with the HMBP ProPAgen 5d was expected
and is in agreement with the literature where phosphoramidate
prodrugs with tBu esters show lower biological activity than
those with other ester motifs. This is because the hydrolysis of
the tBu ester group of the phosphoramidates by esterase
enzymes proceeds much slower than those with Me, iPr, and
Bn esters.
■ CONCLUSION
We reported the application of the aryloxy triester phosphor-
amidate technology to the phosphoantigen HMBP and one of
its synthetic analogues to generate HMBP ProPAgens.
Although the ProPAgens of the native HMBP compound
(6a−d) were of very low stability, those of the synthetic
analogue (5a−d) were more stable. These later ones exhibited
potent activation of Vγ9/Vδ2 T-cells. Notably, HMBP
ProPAgen 5b was the most potent activator of Vγ9/Vδ2 T-
cells, EC50 = 0.45 nM with the other three ProPAgens, 5a, 5c,
and 5d, also showing low nanomolar activation. Impressively,
Vγ9/Vδ2 T-cells activated by HMBP ProPAgens exhibited
potent lysis of urinary bladder carcinoma cancer cells (T24) in
vitro. In terms of speciﬁcity, HMBP ProPAgens, 5a−d, showed
excellent speciﬁcity toward the activation of Vγ9/Vδ2 T-cells as
they had no eﬀects of other T-cells such as CD8+ αβ T-cells.
Eﬀorts aimed at improving the stability of the native HMBP
ProPAgens are currently underway and will be reported in the
future. In conclusion, the application of the aryloxy triester
phosphoramidate prodrug technology to HMBP to generate
HMBP ProPAgens yielded potent and speciﬁc activators of
Vγ9/Vδ2 T-cells. Together, this showcases the promise of this
prodrug technology in the discovery of novel immunother-
apeutic agents.
■ EXPERIMENTAL SECTION
General Information. All of the reactions were carried out under
argon atmosphere and were monitored with analytical thin layer
chromatography (TLC). NMR data were recorded on a Bruker
AV300, AVIII300, AV400, AVIII400, or DRX500 spectrometer in the
deuterated solvents indicated, and the spectra were calibrated on
residual solvent peaks. Chemical shifts (δ) are quoted in ppm, and J
values are quoted in Hz. In reporting spectral data, the following
abbreviations were used: s (singlet), d (doublet), t (triplet), q
(quartet), dd (doublet of doublets), td (triplet of doublets), and m
(multiplet). HPLC was carried out on a DIONEX summit P580
quaternary low-pressure gradient pump with a built-in vacuum
degasser using a Summit UVD 170s UV/vis multichannel detector.
HPLC grade solvents were used. Chromeleon software was used to
visualize and process the obtained chromatograms. Analytical
separations used a ﬂow rate of 1 mL/min and preparative used a
ﬂow rate of 20 mL/min. The purity of the tested compounds was
determined by high-performance liquid chromatography (HPLC)
where all of the tested compounds had ≥95% purity.
1-((tert-Butyldimethylsilyl)oxy)propan-2-one, 2. Hydroxyace-
tone 1 (1.00 g, 13.50 mmol, 1 equiv) and TBSCl (3.05 g, 20.25 mmol,
1.5 equiv) were combined in dry CH2Cl2 (50 mL) under an argon.
Imidazole (2.02 g, 29.70, 2.2 equiv) was then added portionwise at 0
°C. The mixture was allowed to warm to room temperature and left to
stir at that temperature for 2.5 h. The reaction mixture was then
washed with brine (50 mL), extracted with Et2O (50 mL × 3), dried
(MgSO4) and the solvents were removed under reduced pressure to
give a crude oil, which was puriﬁed via column chromatography (10:1
hexane/EtOAc). 2 was obtained as a colorless oil (2.45 g, 95%). δH
NMR (300 MHz, CDCl3): 4.15 (s, 2H, CH2), 2.17 (s, 3H, CH3), 0.93
(s, 9H, CH3), 0.09 (s, 6H, CH3). δC NMR (101 MHz, CDCl3):
209.25, 69.57, 25.98, 25.76, 18.29, −5.51. MS-ESI (%): 211.1 (100, M
+ Na).
Ethyl (E)-4-((tert-Butyldimethylsilyl)oxy)-3-methylbut-2-
enoate, 3. To a 0 °C suspension of NaH (0.20 g, 8.38 mmol, 1
equiv) in dry THF (50 mL) under an argon was added diethyl
phosphonoacetate (1.88 g, 8.38 mmol, 1 equiv) dropwise. The
resulting solution was left to stir for 25 min at 0 °C. Silyl ether 2 (1.5
g, 7.96 mmol, 0.95 equiv) was then added dropwise as a solution in dry
THF (25 mL). The mixture was then stirred at 0 °C for a further 30
min, then warmed to room temperature and stirred for a further 2 h or
until complete via TLC. A saturated solution of brine (50 mL) was
added, dropwise at ﬁrst, then the organic layer was extracted with Et2O
(50 mL × 3), dried (MgSO4) and the solvents were removed to give a
mixture of E/Z isomers (5:1 via 1H NMR) as a crude oil. This was
puriﬁed via column chromatography (10% Et2O in hexane) to give
product 3 as a colorless oil (1.04 g, 50%). δH NMR (300 MHz,
CDCl3): 5.99 (d, J = 1.4 Hz, 1H, CH), 4.17 (q, J = 7.1 Hz, 2H, CH2),
4.11 (d, J = 1.4 Hz, 2H, CH2), 2.05 (s (broad), 3H, CH3), 1.29 (t, J =
7.1 Hz, 3H, CH3), 0.93 (s, 9H, CH3), 0.09 (s, 6H, CH3). δC NMR
(101 MHz, CDCl3): 167.10, 157.16, 113.35, 67.10, 59.59, 25.88, 18.37,
15.44, 14.36, −5.45. MS-ESI (%): 258.2 (8, M), 243.2 (100, M −
CH3).
(E)-4-((tert-Butyldimethylsilyl)oxy)-3-methylbut-2-en-1-ol, 4.
In a ﬂame-dried Schlenk ﬂask were placed ester 3 (0.5 g, 1.93 mmol, 1
equiv) and 20 mL of dry THF, and the resulting mixture was cooled to
0 °C with stirring. Then LiAlH4 (1 M solution in THF) (1.93 mL,
1.93 mmol, 1 equiv) was added dropwise, and the solution was allowed
to warm to room temperature and stirred for 2 h. MeOH (1 mL) was
then added cautiously, after which a saturated solution of sodium
potassium tartrate (30 mL) was added which formed a white gel. This
was stirred overnight at room temperature, and then the phases were
allowed to separate. The organic layer was collected and the aqueous
layer was washed with Et2O (20 mL × 3), dried (MgSO4) and the
solvents were removed under reduced pressure to leave a crude oil.
This was then puriﬁed by column chromatography using hexane/ethyl
acetate (4:1) as an eluant to give product 4 (0.1677 g, 40%) as a
colorless oil. δH (300 MHz, CDCl3) 5.72−5.65 (m, 1H, CH), 4.21 (d,
J = 6.9 Hz, 2H, CH2), 4.04 (s, 2H, CH2), 1.65 (s (broad), 3H, CH3),
0.92 (s, 9H, 3 × CH3), 0.08 (s, 6H, CH3). δC (101 MHz, CDCl3)
138.32, 122.53, 67.66, 59.14, 25.94, 18.41, 13.50, −5.34. MS (ESI)
(%): 239.1 (100, M + Na).
Methyl ((((E)-4-((tert-Butyldimethylsilyl)oxy)-3-methylbut-2-
en-1-yl)oxy)(phenoxy)phosphoryl)-L-alaninate, 5a. To a stirring
solution of alcohol 4 (0.1301 g, 0.6166 mmol, 1 equiv) in dry CH2Cl2
(10 mL) was added methyl phosphorochloridate 9a (0.2055 g, 0.7400
Figure 3. HMBP ProPAgens mediate the speciﬁc lysis of bladder
cancer cells by Vγ9/Vδ2 T-cells. (a) Human T24 urinary bladder
carcinoma cell lines (target) were pulsed for 4 h with 10 nM of the
indicated ProPAgens, media, or 10 μM zoledronate, then cocultured
for 18 h with expanded Vγ9/Vδ2 T cells (eﬀector) at the indicated
target/eﬀector ratios. Speciﬁc killing of target cells was measured by
amine-reactive dead cell marker staining. Data display the mean of n =
2. (b) As in (a) showing the mean ± SD speciﬁc killing of T24 cells at
1:10 target/eﬀector ratio for each indicated treatment, n = 2: (∗) P <
0.05; (∗∗) P < 0.01; determined by one-way ANOVA.
Journal of Medicinal Chemistry Brief Article
DOI: 10.1021/acs.jmedchem.7b01824
J. Med. Chem. 2018, 61, 2111−2117
2114
mmol, 1.2 equiv). The solution was cooled to 0 °C, and NMI (0.10
mL g, 1.2333 mmol, 2 equiv) was added dropwise and the resulting
solution was warmed to room temperature and stirred overnight. Brine
(10 mL) was then added and the organic layer separated oﬀ. The
aqueous layer was then extracted with Et2O (20 mL × 3), the organic
layers were combined, dried (MgSO4) and the solvents removed under
reduced pressure to leave a crude oil. This was then puriﬁed by
column chromatography (4:1 Hex/EtOAc to 1:1 Hex/EtOAc) to give
5a (0.1228 g, 43%) as a colorless oil. δH NMR (400 MHz, CDCl3):
7.31 (t, J = 7.3 Hz, 2H, 2 × CH), 7.21 (t, J = 7.3 Hz, 2H, 2 × CH),
7.14 (t, J = 7.3 Hz, 1H, CH), 5.75−5.59 (m, 1H, CH), 4.72−4.64 (m,
2H, CH2), 4.10−3.97 (m, 3H, CH2 and CH), 3.70 (d, J = 8.8 Hz, 3H,
CH3), 3.53 (dd, J = 18.0, 9.7 Hz, 1H, NH), 1.65 (d, J = 3.5 Hz, 3H,
CH3), 1.37 (t, J = 7.4 Hz, 3H, CH3), 0.91 (s, 9H, 3 × CH3), 0.07 (s,
6H, 2 × CH3). δC NMR (101 MHz, CDCl3): 173.96 (d, J = 6.0 Hz),
150.89 (d, J = 5.7 Hz,), 141.03, 129.58, 124.70, 120.22, 117.86 (d, J =
7.1 Hz), 67.28, 63.28 (t, J = 5.0 Hz), 52.43, 50.11 (d, J = 4.1 Hz),
25.90, 21.05 (d, J = 3.3 Hz), 18.37, 13.59, −5.39. δP NMR (121 MHz,
CDCl3) 2.48, 2.50. HRMS (ESI): found M + Na, 480.1949,
[C21H36NO6SiPNa] requires 480.1947.
Benzyl ((((E)-4-((tert-Butyldimethylsilyl)oxy)-3-methylbut-2-
en-1-yl)oxy)(phenoxy)phosphoryl)-L-alaninate, 5b. Prepared
under the same procedure as described for 5a using alcohol 4 (0.16
g, 0.77 mmol, 1 equiv), benzyl phosphorchloridate 9b (0.32 g, 0.92
mmol, 1.2 equiv), and dry Et3N (0.22 mL, 1.5496 mmol, 2 equiv) to
give a crude yellow oil which was then puriﬁed by column
chromatography (4:1 Hex/EtOAc to 2:3 Hex/EtOAc) to aﬀord 5b
(0.1306 g, 31%) as a colorless oil. δH NMR (400 MHz, CDCl3) δ
7.44−7.06 (m, 10H, Ph), 5.66 (m, 1H, CH), 5.18−5.09 (m, 2H, CH2),
4.71−4.61 (m, 2H, CH2), 4.13−4.04 (m, 1H, CH), 4.02 (d, J = 5.3 Hz,
2H, CH2), 3.59−3.45 (m, 1H, NH), 1.63 (d, J = 5.1 Hz, 3H, CH3),
1.38 (t, J = 6.9 Hz, 3H, CH3), 0.91 (s, 9H, CH3), 0.06 (s, 6H, 2 ×
CH3). δC NMR (101 MHz, CDCl3): 173.32 (2s), 150.88 (s), 141.06
(2s), 135.28, 129.59 (2s), 128.64 (2s), 128.48 (2s), 128.19 (2s),
124.71 (2s), 120.23 (s (broad)), 117.87 (2s), 67.32 (2s (broad)),
67.18 (2s (broad)), 63.35 (2s), 50.25 (2s), 25.91 (2s), 21.11 (2s),
13.59 (2s), −5.37. δP NMR (121 MHz, CDCl3): 2.38, 2.56. HRMS
(ESI): found M + Na, 556.2262, [C27H40NO6PSiNa] requires
556.2260.
Isopropyl ((((E)-4-((tert-Butyldimethylsilyl)oxy)-3-methylbut-
2-en-1-yl)oxy)(phenoxy)phosphoryl)-L-alaninate, 5c. Prepared
under the same procedure as described for 5a using alcohol 4 (0.23
g, 1.08 mmol, 1 equiv), isopropyl phosphorchloridate 9c (0.39 g, 1.29
mmol, 1.2 equiv), and dry Et3N (0.30 mL, 2.16 mmol, 2 equiv) to give
a crude yellow oil which was then puriﬁed by column chromatography
(4:1 Hex/EtOAc) to aﬀord 5c (0.1914 g, 36%) as a colorless oil. δH
NMR (400 MHz, CDCl3) 7.30 (td, J = 8.5, 2.1 Hz, 2H, 2 × CH), 7.20
(td, J = 7.5, 0.9 Hz, 2H, 2 × CH), 7.16−7.08 (m, 1H, CH), 5.66 (q, J =
7.2 Hz, 1H, CH), 5.06−4.92 (m, 1H, CH), 4.75−4.59 (m, 2H, CH2),
4.02 (s, 2H, CH2), 4.00−3.88 (m, 1H, CH), 3.60−3.48 (m, 1H, NH),
1.63 (s, 3H, CH3), 1.38−1.32 (m, 3H, CH3), 1.26−1.17 (m, 6H, 2 ×
CH3), 0.90 (s, 9H, 3 × CH3), 0.05 (s, J = 4.2 Hz, 6H, 2 × CH3). δC
NMR (101 MHz, CDCl3) 173.00 (2d, J = 4.13 Hz), 150.92 (t, J = 6.7
Hz), 140.96, 129.57, 124.68 (s (broad)), 120.23 (t, J = 4.6 Hz), 117.92
(2s), 69.11, 67.30, 63.28 (t, J = 5.1 Hz), 50.30 (2s), 25.90, 21.66 (2s),
21.09 (2s), 18.37, 13.59, −5.39. δP NMR (121 MHz, CDCl3): 2.62,
2.65. HRMS (ESI): found M + Na, 508.2258, [C23H40NO6PSiNa]
requires 508.2260.
tert-Butyl ((((E)-4-((tert-Butyldimethylsilyl)oxy)-3-methylbut-
2-en-1-yl)oxy)(phenoxy)phosphoryl)-L-alaninate, 5d. Prepared
under the same procedure as described for 5a using alcohol 4 (0.14 g,
0.65 mmol, 1 equiv), tert-butyl phosphorchloridate 9d (0.25 g, 0.78
mmol, 1.2 equiv), and dry NMI (0.11 mL, 1.30 mmol, 2 equiv) to give
a crude yellow oil which was then puriﬁed by column chromatography
(4:1 Hex/EtOAc) to aﬀord 5d (0.1832 g, 56%) as a colorless oil. δH
NMR (400 MHz, CDCl3): 7.29 (t, J = 7.2 Hz, 2H, 2 × CH), 7.22 (t, J
= 7.2, 2H, 2 × CH), 7.12 (t, J = 7.2 Hz, 1H, CH), 5.68 (qd, J = 7.2, 1.3
Hz, 1H, CH), 4.74−4.62 (m, 2H, CH2), 4.02 (s, 2H, CH2), 3.95−3.83
(m, 1H, CH), 3.73−3.62 (m, 1H, NH), 1.64 (s, 3H, CH3), 1.43 (2s,
9H, 3 × CH3), 1.33 (2d, J = 3.1 Hz, 3H, CH3), 0.91 (s, 9H, 3 × CH3),
0.07 (s, 6H, 2 × CH3). δC NMR (101 MHz, CDCl3): 172.64 (2d, J =
4.1 Hz), 150.94 (t, J = 6.2 Hz), 140.76, 129.49, 124.55, 120.21 (t, J =
4.8 Hz), 118.01 (2s (broad)), 81.69, 67.27, 63.15 (t, J = 5.0 Hz), 50.66
(2s), 27.86, 25.87, 21.06 (2s), 18.31, 13.53, −5.41. δP NMR (121
MHz, CDCl3): 2.82 (s (broad)). HRMS (ESI): found M + Na,
522.2415, [C24H42NO6SiPNa] requires 522.2417.
Methyl ((((E)-4-Hydroxy-3-methylbut-2-en-1-yl)oxy)-
(phenoxy)phosphoryl)-L-alaninate, 6a. The silyl ether 5a (0.12
g, 0.26 mmol, 1 equiv) was placed in a ﬂask containing MeOH (3 mL).
HCl (1.25 M in MeOH, 0.0215 mL, 0.0268 mmol, 0.1 equiv) was then
added at 0 °C, and the resulting solution was warmed to room
temperature while stirring for 40 min, until reaction was complete via
TLC, upon which it was neutralized with sodium bicarbonate. The
mixture was then ﬁltered and MeOH removed under reduced
pressure. Brine (10 mL) and CH2Cl2 (10 mL) were then added.
The organic layer was collected, and the aqueous layer was extracted
with CH2Cl2 (10 mL × 3). The organic layers were combined, dried
(MgSO4) and the solvents removed under reduced pressure to leave a
crude brown oil. This was then puriﬁed by column chromatography
(4:1 Hex/EtOAc) to leave 6a (0.0920 g, 49%) as a colorless oil. δH
NMR (400 MHz, CDCl3): 7.32 (t, J = 7.8 Hz, 2H, 2 × CH), 7.25−
7.18 (m, 2H, 2 × CH), 7.15 (t, J = 7.3 Hz, 1H, CH), 5.67 (dtd, J =
12.5, 7.0, 1.4 Hz, 1H, CH), 4.78−4.58 (m, 2H, CH2), 4.16−3.93 (m,
3H, CH2 and CH), 3.71 (d, J = 8.4 Hz, 3H, CH3), 3.64−3.43 (m, 1H,
NH), 1.70 (s, 3H, CH3), 1.37 (t, J = 7.0 Hz, 3H, CH3). δC NMR (101
MHz, CDCl3): 174.11 (2s), 150.78 (2s), 141.65 (s (broad)), 129.60,
124.76, 120.19 (t, J = 5.5 Hz), 118.48 (t, J = 7.2 Hz), 67.19, 63.49 (t, J
= 5.7 Hz), 52.47 (s), 50.14 (2s), 20.95 (t, J = 5.3 Hz), 13.78. δP NMR
(121 MHz, CDCl3): 2.42, 2.57. HRMS (ESI): found M + Na,
366.1081, [C15H22NO6PNa] requires 366.1082.
Benzyl ((((E)-4-Hydroxy-3-methylbut-2-en-1-yl)oxy)-
(phenoxy)phosphoryl)-L-alaninate, 6b. Prepared following the
same procedure as described for 6a using silyl ether 5b (0.13 g, 0.24
mmol, 1 equiv) and HCl (1.25 M in MeOH, 0.19 mL, 0.24 mmol, 1
equiv) in dry MeOH (5 mL), to give a crude brown oil after 2 h. This
was then puriﬁed by column chromatography (1:1 Hex/EtOAc to 1:4
Hex/EtOAc) to aﬀord 6b (0.0207 g, 20%) as a colorless oil. δH NMR
(400 MHz, CDCl3): 7.53−7.02 (m, 10H, Ph), 5.64 (dtd, J = 21.5, 7.0,
1.3 Hz, 1H, CH), 5.13 (d, J = 11.7 Hz, 2H, CH2), 4.75−4.57 (m, 2H,
CH2), 4.15−4.01 (m, 1H, CH), 3.99 (d, J = 8.9 Hz, 2H, CH2), 3.65−
3.50 (m, 1H, NH), 1.97 (s (broad), 1H, OH), 1.68 (d, J = 4.8 Hz, 3H,
CH3), 1.37 (t, J = 7.0 Hz, 3H, CH3). δC NMR (100 MHz, CDCl3):
173.45 (2d, J = 3.3 Hz), 150.82 (t, J = 6.1 Hz), 141.44 (s (broad)),
135.23, 129.60, 128.65, 128.51 (2s), 128.20, 124.78, 120.23 (2d, J =
5.0 Hz), 118.81 (2d, J = 6.5 Hz), 67.43, 67.24, 63.40 (t, J = 5.8 Hz),
50.29 (2s), 29.70, 13.81. δP NMR (121 MHz, CDCl3): 2.36, 2.53.
HRMS (ESI): found M + Na, 442.1392, [C21H26NO6PNa] requires
442.1395.
Isopropyl ((((E)-4-Hydroxy-3-methylbut-2-en-1-yl)oxy)-
(phenoxy)phosphoryl)-L-alaninate, 6c. Prepared following the
same procedure as described for 6a using silyl ether 5c (0.19 g, 0.39
mmol, 1 equiv) and HCl (1.25 M in MeOH, 0.03 mL, 0.0364 mmol,
0.1 equiv) in dry MeOH (5 mL), to give a crude brown oil after 1.5 h.
This was then puriﬁed by column chromatography (1:1 Hex/EtOAc)
to aﬀord 6c (0.0725 g, 49%) as a colorless oil. δH NMR (400 MHz,
CDCl3): 7.34−7.28 (m, 2H, CH), 7.21 (t, J = 7.4 Hz, 2H, 2 × CH),
7.14 (t, J = 7.3 Hz, 1H, CH), 5.73−5.61 (m, 1H, CH), 5.08−4.91 (m,
1H, CH), 4.76−4.57 (m, 2H, CH2), 4.04−3.86 (m, 3H, CH2 & CH),
3.77−3.64 (m, 1H, NH), 2.89 (s, 1H, OH), 1.68 (s, 3H, CH3), 1.34 (t,
J = 6.5 Hz, 3H, CH3), 1.22 (ddd, J = 11.7, 7.0, 5.5 Hz, 6H, 2 × CH3).
δC NMR (101 MHz, CDCl3): 173.21 (2s), 150.90 (t, J = 6.2 Hz),
141.69 (s, (broad)), 129.66, 124.81, 120.28 (2d, J = 4.8 Hz), 118.63 (t,
J = 5.7 Hz), 69.28, 67.26, 63.52 (t, J = 5.1 Hz), 50.37 (2s), 21.71 (2s),
21.19−20.94 (m), 13.85. δP NMR (121 MHz, CDCl3): 2.54, 2.68.
tert-Butyl ((((E)-4-Hydroxy-3-methylbut-2-en-1-yl)oxy)-
(phenoxy)phosphoryl)-L-alaninate, 6d. Prepared following the
same procedure as described for 6a using silyl ether 5d (0.1832 g,
0.3666 mmol, 1 equiv) and HCl (1.25 M in MeOH, 0.0293 mL,
0.0366 mmol, 0.1 equiv) in dry MeOH (3 mL), to give a crude brown
oil. This was then puriﬁed by column chromatography (2:3 Hex/
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EtOAc) to aﬀord 6d (0.0983 g, 74%) as a colorless oil. δH NMR (400
MHz, CDCl3): 7.31 (t, J = 7.2 Hz, 2H, 2 × CH), 7.21 (dd, J = 7.6, 6.6
Hz, 2H, 2 × CH), 7.13 (t, J = 7.3 Hz, 1H, CH), 5.73−5.61 (m, 1H,
CH), 4.75−4.59 (m, 2H, CH2), 3.99 (s (broad), 2H, CH2), 3.96−3.80
(m, 1H, CH), 3.72−3.61 (m, 1H, NH), 2.96 (s (broad), 1H, OH),
1.68 (s, 3H, CH3), 1.43 (2s, 9H, CH3), 1.36−1.29 (t, J = 6.3 Hz, 3H,
CH3). δC NMR (101 MHz, CDCl3): 172.79 (2s), 150.86 (t, J = 6.1
Hz), 141.57, 129.58, 124.69, 120.22 (2d, J = 4.9 Hz), 118.61 (2s),
81.97, 67.19, 63.40 (t, J = 5.1 Hz), 50.70, 27.89, 21.11 (2d, J = 4.6 Hz),
13.79. δP NMR (121 MHz, CDCl3): 2.70, 2.79. HRMS (ESI): found
M + Na, 408.1554, [C18H28NO6PNa] requires 408.1554.
Methyl (Chloro(phenoxy)phosphoryl)-L-alaninate, 9a. Phenyl
phosphorodichloridate 7 (0.2 g, 0.95 mmol, 1 equiv) and L-alanine
methyl ester hydrogen chloride (0.13 g, 0.95 mmol, 1 equiv) were
combined in dry CH2CL2 (10 mL) under an argon ﬂow at −78 °C and
stirred at −78 °C for 20 min. Dry Et3N (0.26 mL, 1.90 mmol, 2 equiv)
was then added dropwise over 15 min and the reaction stirred at −78
°C for a further 30 min. The temperature is then raised to room
temperature and the reaction stirred for a further 3.5 h. The solvents
are removed under reduced pressure, and the mixture is ﬁltered and
washed with Et2O, which is removed under reduced pressure to give a
crude oil. This is then puriﬁed by column chromatography (7:3 Hex/
EtOAc) to give 9a as a colorless oil (0.14 g, 54%), which is stored
under argon. δH NMR (300 MHz, CDCl3): 7.40−7.34 (m, 2H, 2 ×
CH), 7.29−7.23 (m, 3H, 2 × CH), 4.66−4.49 (m, 1H, NH), 4.28−
4.12 (m, 1H, CH), 3.78 (2s, 3H, CH3), 1.51 (2 × dd, J = 4.1, 0.5 Hz,
3H, CH3). δC (101 MHz, CDCl3): 173.11 (2d, J = 8.8 Hz), 149.73
(2d, J = 7.14 Hz), 129.90, 125.99, 120.54 (2d, J = 1.4 Hz), 52.80 (2s),
50.39 (2d, J = 1.5 Hz), 20.51 (2d, J = 1.5 Hz). δP NMR (121 MHz,
CDCl3): 7.62, 7.94.
Benzyl (Chloro(phenoxy)phosphoryl)-L-alaninate, 9b. Fol-
lowed the same procedure as described for 9a using 7 (0.35 mL,
3.32 mmol, 1 equiv), Et3N (0.63 mL, 4.64 mmol, 2 equiv), and L-
alanine benzyl ester hydrogen chloride (0.5 g, 2.32 mmol, 1 equiv) to
give phosphorchloridate 9b (0.505 g, 95%). δH NMR (300 MHz,
CDCl3): 7.42−7.32 (m, 7H, Ph), 7.25−7.20 (m, 3H, Ph), 5.21 (2s,
2H, CH2), 4.34−4.15 (m, 2H, CH and N-H), 1.52 (dd, J = 6.6, 2.4
Hz, 3H, CH3). δC NMR (101 MHz, CDCl3): 172.52 (dd, J = 11.6, 8.7
Hz), 149.75 (dd, J = 11.6. 8.7 Hz), 135.05 (d, J = 5.8 Hz, C-10),
129.92, 128.68, 128.59, 128.33, 125.99, 120.57, 67.60, 50.67, 20.47 (t, J
= 4.5 Hz). δP NMR (121 MHz, CDCl3): 7.49, 7.85.
Isopropyl (Chloro(phenoxy)phosphoryl)-L-alaninate, 9c. Fol-
lowedthe same procedure as described for 9a using 7 (0.62 mL, 4.18
mmol, 1 equiv), Et3N (1.13 mL, 8.36 mmol, 2 equiv), and L-alanine
isopropyl ester hydrogen chloride (0.700 g, 4.18 mmol, 1 equiv) to
give phosphorchloridate 9c (1.185 g, 93%). δH NMR (300 MHz,
CDCl3): 7.41−7.34 (m, 2H, 2 × CH), 7.30−7.21 (m, 3H, 3 × CH),
5.15−5.01 (m, 1H, CH), 4.50−4.31 (m, 1H, NH), 4.22−4.04 (m, 1H,
CH), 1.50 (dd, J = 7.0, 2.1 Hz, 3H, CH3), 1.34−1.22 (m, 6H, 2 ×
CH3). δC NMR (101 MHz, CDCl3): 172.15 (dd, J = 13.9, 9.2 Hz),
149.76 (t, J = 7.0 Hz), 129.93, 125.98, 120.56 (d, J = 4.9 Hz), 69.79 (d,
J = 10.5 Hz), 50.70 (2s), 21.67 (2s), 20.55 (d, J = 4.4 Hz). δP NMR
(121 MHz, CDCl3): 7.76, 8.11.
tert-Butyl (Chloro(phenoxy)phosphoryl)-L-alaninate, 9d. Fol-
lowed the same procedure as described for 9a using 7 (0.22 mL, 1.5
mmol, 1 equiv), Et3N (0.42 mL, 3 mmol, 2 equiv), and L-alanine tert-
butyl ester hydrogen chloride (0.27 g, 1.5 mmol, 1 equiv) to give
phosphorchloridate 9d (0.44 g, 90%). δH NMR (400 MHz, CDCl3):
7.37 (t, J = 7.8 Hz, 2H, 2 × CH), 7.30−7.22 (m, 3H, 2 × CH), 4.46−
4.24 (m, 1H, NH), 4.16−3.97 (m, 1H, CH), 1.50−1.46 (m, 12H, 4 ×
CH3). δC NMR (101 MHz, CDCl3): 171.77 (dd, J = 15.8, 9.4 Hz),
149.80, 129.92, 125.96, 120.57 (d, J = 5.0 Hz), 82.70 (2s), 51.09 (2s),
27.93, 20.63. δP NMR (121 MHz, CDCl3): 7.85, 8.24.
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